At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,023 enrolled
Drug / intervention
treatment with NOACs or VKAsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
New Oral Anticoagulants in Stroke Patients-Long Term Prevention of Recurrent Stroke in Patients With Atrial Fibrillation- a National Prospective Registry (NOACISP Long Term)
In Brief
An observational study evaluating treatment with NOACs or VKAs for Stroke and Atrial Fibrillation. Completed, enrolled 1,023 participants across 2 sites.
Detailed Summary
Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world" setting at a stroke centre.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Atrial Fibrillation
CountriesSwitzerland
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedFeb 2019
Primary CompletionAug 2021
TodayJul 2026
First PostedFeb 1, 2019
Enrollment StartMar 1, 2013
Primary CompletionAug 1, 2021
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 7.4 years ago
Interventions
treatment with NOACs or VKAsother
treatment with NOACs or VKAs initiated or continued for prevention of ischemic events